跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 11 天前AI 评分39

Cardiol Therapeutics 提交 6-K,披露与 Jefferies LLC 的市场增发计划公告

6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

AI 导读

Cardiol Therapeutics 提交 Form 6-K,随附 11 月 3 日新闻稿,宣布与 Jefferies LLC 达成市场增发计划。公司按 Form 40-F 提交年度报告。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

 
 

SUBMITTED HEREWITH

Exhibits

Exhibit   Description
     
99.1   News Release dated November 3, 2026 - Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CARDIOL THERAPEUTICS INC.
  (Registrant)
     
Date: November 3, 2026 By: /s/ Christopher Waddick
    Christopher Waddick
  Title: Chief Financial Officer

来源:SEC EDGAR · 本站存档